134 related articles for article (PubMed ID: 38745582)
1. Continuing Education Case Study Quiz.
Hosp Pharm; 2016 Mar; 51(3):263-265. PubMed ID: 38745582
[TBL] [Abstract][Full Text] [Related]
2. Continuing education case study quiz.
Hosp Pharm; 2013 Apr; 48(4):332-3. PubMed ID: 24421483
[TBL] [Abstract][Full Text] [Related]
3. Continuing education case study quiz.
Hosp Pharm; 2013 Feb; 48(2):153-5. PubMed ID: 24550570
[TBL] [Abstract][Full Text] [Related]
4. Continuing education case study quiz.
Hosp Pharm; 2013 Mar; 48(3):241-2. PubMed ID: 24421468
[TBL] [Abstract][Full Text] [Related]
5. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
6. Continuing education case study quiz.
Hosp Pharm; 2013 Jan; 48(1):57-9. PubMed ID: 24550569
[TBL] [Abstract][Full Text] [Related]
7. Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study.
Yasaka M; Yokota H; Suzuki M; Asakura H; Yamane T; Ogi Y; Kimoto T; Nakayama D
Cardiol Ther; 2023 Dec; 12(4):723-740. PubMed ID: 37845427
[TBL] [Abstract][Full Text] [Related]
8. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
[TBL] [Abstract][Full Text] [Related]
9. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
Miyares MA; Kuyumjian Y; Eaves S; Dollard E
J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
[TBL] [Abstract][Full Text] [Related]
10. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
Van der Wall SJ; Lopes RD; Aisenberg J; Reilly P; van Ryn J; Glund S; Elsaesser A; Klok FA; Pollack CV; Huisman MV
Circulation; 2019 Feb; 139(6):748-756. PubMed ID: 30586692
[TBL] [Abstract][Full Text] [Related]
11. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
[TBL] [Abstract][Full Text] [Related]
12. Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?
Miller L; Ferreira JA; Tucker C
J Emerg Med; 2017 Mar; 52(3):341-347. PubMed ID: 27727040
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
[TBL] [Abstract][Full Text] [Related]
14. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
Pollack CV
Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
[TBL] [Abstract][Full Text] [Related]
15. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
[TBL] [Abstract][Full Text] [Related]
16. Evidence supporting idarucizumab for the reversal of dabigatran.
Pollack CV
Am J Emerg Med; 2016 Nov; 34(11S):33-38. PubMed ID: 27697436
[TBL] [Abstract][Full Text] [Related]
17. Assessment of patients post reversal with idarucizumab.
Raco V; Ahuja T; Green D
J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience with reversal of dabigatran by idarucizumab.
Haastrup SB; Hellfritzsch M; Nybo M; Hvas AM; Grove EL
Thromb Res; 2021 Jan; 197():179-184. PubMed ID: 33227654
[TBL] [Abstract][Full Text] [Related]
20. Idarucizumab for Reversal of Dabigatran in Early/Emergency Surgeries: A Case Series.
Peacock WF; Grotta JC; Steiner T
J Emerg Med; 2019 Dec; 57(6):e167-e173. PubMed ID: 31662218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
